Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA

What Was Tested

This randomized controlled trial paper looks at Tirzepatide.

Obstructive sleep apnea (OSA) is a common disorder characterized by repetitive collapse of the upper airway during sleep.

Given that excess adiposity is a known risk factor for OSA, the researchers aimed to descriptively assess the association of tirzepatide, a GIP/GLP-1 receptor agonist, with changes in AHI, hypoxic burden, body weight, and blood pressure in different patient populations based on baseline characteristics such as age, sex, BMI, AHI, and neck circumference.

Why It Was Studied

This research may help them better understand the relationship between baseline characteristics and different OSA treatment responses and may stimulate future studies in this area.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Baseline subgroup analyses were conducted in participants with non-missing relevant baseline measurements.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Tirzepatide.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Tirzepatide, Sleep Apnea, Obstructive, Obesity, Polysomnography and Blood Pressure.

The authors tagged it with the keywords Lung, Obstructive sleep apnea and Respiration.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine), a journal based in Switzerland.

More context: the Tirzepatide compound page, all human trials.